CIK: 0001346824
Total reported value
$9.4B
Reporting period: 2026-03-31 · Number of holdings: 86
RA CAPITAL MANAGEMENT, L.P. disclosed 86 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $9.4B and a quarterly turnover rate of 44.2%.
Browse other institutions with $1B to $10B AUMBrowse other institutions starting with "R"
Ra Capital Management, L.p.'s disclosed holdings carry a Herfindahl concentration index of 0.083 — mathematically equivalent to about 12 equally-sized positions, well below its 86 actual disclosed holdings. That gap points to a strategy built around a small core of high-conviction bets rather than broad diversification.
Position sizes vary widely across the portfolio (a coefficient of variation of 2.48), with a handful of outsized bets alongside many smaller positions.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 1% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Add ASND
0.0% $159.3M
Add PCVX
+7.0% $172.0M
Add TYRA
0.0% $146.5M
Add DNTH
+62.0% $152.8M
Trim RYTM
0.0% -$133.8M
Trim WVE
+48.2% -$113.9M
Showing top 85 holdings (of 86 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | Stock-Other | 24.92% | +2.46% | — | |
| 2 | PCVX | Vaxcyte INC | Stock-Other | 7.07% | +2.00% | +6.99% | |
| 3 | RYTM | Rhythm Pharmaceuticals INC | Stock-Other | 6.14% | -1.17% | — | |
| 4 | TYRA | Tyra Biosciences INC | Stock-Other | 4.95% | +1.66% | — | |
| 5 | SION | Sionna Therapeutics INC | Stock-Other | 4.21% | — | — | |
| 6 | EWTX | Edgewise Therapeutics INC | Stock-Other | 3.48% | +0.83% | — | |
| 7 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 3.24% | -0.19% | — | |
| 8 | NUVL | Nuvalent Inc-a | Stock-Other | 2.75% | +0.81% | +34.79% | |
| 9 | DNTH | Dianthus Therapeutics INC | Stock-Other | 2.32% | +1.64% | +62.05% | |
| 10 | MLYS | Mineralys Therapeutics INC | Stock-Other | 2.21% | -0.51% | +5.04% | |
| 11 | SGP | Spyglass Pharma INC | Stock-Other | 2.20% | +2.20% | NEW | |
| 12 | WVE | Wave Life Sciences Ltd. | Stock-Other | 2.07% | -1.10% | +48.19% | |
| 13 | SEPN | Septerna INC | Stock-Other | 1.78% | -0.22% | — | |
| 14 | IRON | Disc Medicine INC | Stock-Other | 1.66% | — | +23.99% | |
| 15 | JANX | Janux Therapeutics INC | Stock-Other | 1.65% | — | — | |
| 16 | BCRX | Biocryst Pharmaceuticals INC | Stock-Other | 1.60% | +0.34% | — | |
| 17 | BCAX | Bicara Therapeutics INC | Stock-Other | 1.53% | +0.33% | +4.31% | |
| 18 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.28% | — | — | |
| 19 | GHRS | GH Research PLC | Stock-Other | 1.14% | — | — | |
| 20 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.14% | +1.14% | NEW | |
| 21 | TSHA | Taysha Gene Therapies INC | Stock-Other | 1.12% | -0.21% | — | |
| 22 | VOR | Vor Biopharma INC | Stock-Other | 1.02% | +0.30% | — | |
| 23 | GERN | Geron CORP | Stock-Other | 1.01% | — | — | |
| 24 | SPRY | Ars Pharmaceuticals INC | Stock-Other | 0.92% | -0.38% | — | |
| 25 | SRPT | Sarepta Therapeutics INC | Stock-Healthcare | 0.90% | +0.90% | NEW | |
| 26 | SYRE | Spyre Therapeutics INC | Stock-Other | 0.87% | +0.33% | — | |
| 27 | EVMN | Evommune INC | Stock-Other | 0.85% | +0.24% | +1.04% | |
| 28 | CLYM | Climb Bio INC | Stock-Other | 0.82% | — | +0.06% | |
| 29 | SLDB | Solid Biosciences INC | Stock-Other | 0.71% | +0.37% | +60.72% | |
| 30 | ARTV | Artiva Biotherapeutics INC | Stock-Other | 0.67% | +0.24% | — | |
| 31 | DMRA | Damora Therapeutics INC | Stock-Other | 0.66% | +0.66% | NEW | |
| 32 | XNCR | Xencor INC | Stock-Other | 0.63% | +0.63% | NEW | |
| 33 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 0.58% | — | — | |
| 34 | JBIO | Jade Biosciences INC | Stock-Other | 0.55% | — | — | |
| 35 | ABOS | Acumen Pharmaceuticals INC | Stock-Other | 0.52% | +0.20% | +40.59% | |
| 36 | FDMT | 4d Molecular Therapeutics In | Stock-Other | 0.50% | — | -10.67% | |
| 37 | FULC | Fulcrum Therapeutics INC | Stock-Other | 0.49% | -0.21% | — | |
| 38 | CAPR | Capricor Therapeutics INC | Stock-Other | 0.49% | — | — | |
| 39 | IPSC | Century Therapeutics INC | Stock-Other | 0.43% | +0.43% | NEW | |
| 40 | OLMA | Olema Pharmaceuticals INC | Stock-Other | 0.41% | -0.26% | — | |
| 41 | LENZ | Lenz Therapeutics INC | Stock-Other | 0.41% | -0.27% | — | |
| 42 | MNPR | Monopar Therapeutics INC | Stock-Other | 0.39% | — | — | |
| 43 | PEPG | Pepgen INC | Stock-Other | 0.38% | -0.96% | — | |
| 44 | DSGN | Design Therapeutics INC | Stock-Other | 0.34% | +0.20% | +103.44% | |
| 45 | MIRM | Mirum Pharmaceuticals INC | Stock-Other | 0.31% | +0.31% | NEW | |
| 46 | BIOA | Bioage Labs INC | Stock-Other | 0.31% | +0.31% | NEW | |
| 47 | LXEO | Lexeo Therapeutics INC | Stock-Other | 0.30% | -0.21% | — | |
| 48 | ASMB | Assembly Biosciences INC | Stock-Other | 0.30% | — | — | |
| 49 | RZLT | Rezolute INC | Stock-Other | 0.30% | — | — | |
| 50 | AKTS | Aktis Oncology INC | Stock-Other | 0.28% | +0.28% | NEW |
Performance for Q3 2026
+12%
Performance Last 4 Quarters
+31.9%
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 86 | $9.4B | 44 | |
| 2025-12-31 | 72 | $9.8B | 43 | |
| 2025-09-30 | 68 | $8.1B | 57 | |
| 2025-06-30 | 64 | $5.9B | 0 | |
| 2025-03-31 | 86 | $6.0B | 100 | |
| 2024-12-31 | 90 | $7.5B | 0 | |
| 2024-09-30 | 82 | $8.7B | 0 | |
| 2024-06-30 | 79 | $7.6B | 0 | |
| 2024-03-31 | 75 | $7.8B | 0 | |
| 2023-12-31 | 62 | $6.4B | 0 | |
| 2023-09-30 | 65 | $5.0B | 0 | |
| 2023-06-30 | 54 | $5.3B | 0 | |
| 2023-03-31 | 59 | $4.4B | 0 | |
| 2022-12-31 | 70 | $4.9B | 0 | |
| 2022-09-30 | 81 | $4.7B | 0 | |
| 2022-06-30 | 88 | $3.8B | 0 | |
| 2022-03-31 | 96 | $4.6B | 0 | |
| 2021-12-31 | 97 | $5.7B | 0 | |
| 2021-09-30 | 95 | $7.2B | 0 | |
| 2021-06-30 | 92 | $6.2B | 49 | |
| 2021-03-31 | 82 | $6.6B | 52 | |
| 2020-12-31 | 82 | $7.2B | 59 | |
| 2020-09-30 | 70 | $5.5B | 45 | |
| 2020-06-30 | 57 | $5.1B | 74 | |
| 2020-03-31 | 48 | $3.2B | 60 | |
| 2019-12-31 | 34 | $3.3B | 84 | |
| 2019-09-30 | 32 | $1.7B | 41 | |
| 2019-06-30 | 25 | $1.9B | 43 | |
| 2019-03-31 | 29 | $2.3B | 44 | |
| 2018-12-31 | 25 | $1.7B | 50 | |
| 2018-09-30 | 26 | $1.9B | 35 | |
| 2018-06-30 | 27 | $1.5B | 47 | |
| 2018-03-31 | 31 | $1.3B | 32 | |
| 2017-12-31 | 27 | $1.2B | 67 | |
| 2017-09-30 | 27 | $1.1B | 43 | |
| 2017-06-30 | 22 | $871.4M | 50 | |
| 2017-03-31 | 24 | $815.3M | 38 | |
| 2016-12-31 | 26 | $687.2M | 60 | |
| 2016-09-30 | 31 | $969.4M | 45 | |
| 2016-06-30 | 32 | $722.2M | 34 | |
| 2016-03-31 | 42 | $782.3M | 61 | |
| 2015-12-31 | 37 | $1.0B | 67 | |
| 2015-09-30 | 47 | $696.3M | 76 | |
| 2015-06-30 | 59 | $994.1M | 66 | |
| 2015-03-31 | 57 | $1.0B | 50 | |
| 2014-12-31 | 51 | $930.5M | 70 | |
| 2014-09-30 | 46 | $846.3M | 62 | |
| 2014-06-30 | 28 | $989.3M | 71 | |
| 2014-03-31 | 35 | $1.4B | 62 | |
| 2013-12-31 | 31 | $858.5M | 69 | |
| 2013-09-30 | 39 | $958.1M | 44 | |
| 2013-06-30 | 29 | $754.0M | 0 |
Ra Capital Management, L.p.'s most significant position changes for 2026-03-31: Sold out: Cidara Therapeutics INC (CDTX); Sold out: Avidity Biosciences INC (RNAGBP); New buy: Spyglass Pharma INC (SGP); New buy: Zai Lab Ltd-adr (ZLAB); New buy: Sarepta Therapeutics INC (SRPT).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ASND | Ascendis Pharma A/S | +2.5% | — | Unchanged |
| 2 | PCVX | Vaxcyte INC | +2% | +6.99% | Add |
| 3 | TYRA | Tyra Biosciences INC | +1.7% | — | Unchanged |
| 4 | DNTH | Dianthus Therapeutics INC | +1.6% | +62.05% | Add |
| 5 | EWTX | Edgewise Therapeutics INC | +0.8% | — | Unchanged |
| 6 | NUVL | Nuvalent Inc-a | +0.8% | +34.79% | Add |
| 7 | SLDB | Solid Biosciences INC | +0.4% | +60.72% | Add |
| 8 | BCRX | Biocryst Pharmaceuticals INC | +0.3% | — | Unchanged |
| 9 | SYRE | Spyre Therapeutics INC | +0.3% | — | Unchanged |
| 10 | BCAX | Bicara Therapeutics INC | +0.3% | +4.31% | Add |
| 11 | VOR | Vor Biopharma INC | +0.3% | — | Unchanged |
| 12 | ARTV | Artiva Biotherapeutics INC | +0.2% | — | Unchanged |
| 13 | EVMN | Evommune INC | +0.2% | +1.04% | Add |
| 14 | ABOS | Acumen Pharmaceuticals INC | +0.2% | +40.59% | Add |
| 15 | DSGN | Design Therapeutics INC | +0.2% | +103.44% | Add |
| 16 | GRAL | Grail INC | -0.2% | — | Unchanged |
| 17 | NAMS | NewAmsterdam Pharma Company N.V. | -0.2% | — | Unchanged |
| 18 | TSHA | Taysha Gene Therapies INC | -0.2% | — | Unchanged |
| 19 | FULC | Fulcrum Therapeutics INC | -0.2% | — | Unchanged |
| 20 | LXEO | Lexeo Therapeutics INC | -0.2% | — | Unchanged |
| 21 | SEPN | Septerna INC | -0.2% | — | Unchanged |
| 22 | OLMA | Olema Pharmaceuticals INC | -0.3% | — | Unchanged |
| 23 | LENZ | Lenz Therapeutics INC | -0.3% | — | Unchanged |
| 24 | SPRY | Ars Pharmaceuticals INC | -0.4% | — | Unchanged |
| 25 | MLYS | Mineralys Therapeutics INC | -0.5% | +5.04% | Add |
| 26 | PEPG | Pepgen INC | -1% | — | Unchanged |
| 27 | WVE | Wave Life Sciences Ltd. | -1.1% | +48.19% | Add |
| 28 | RYTM | Rhythm Pharmaceuticals INC | -1.2% | — | Unchanged |
| 29 | CDTX | Cidara Therapeutics INC | — | EXIT | Sold out |
| 30 | RNAGBP | Avidity Biosciences INC | — | EXIT | Sold out |
| 31 | SGP | Spyglass Pharma INC | — | NEW | New buy |
| 32 | ZLAB | Zai Lab Ltd-adr | — | NEW | New buy |
| 33 | SRPT | Sarepta Therapeutics INC | — | NEW | New buy |
| 34 | ACLXGBX | Arcellx INC | — | EXIT | Sold out |
| 35 | BLTE | Belite Bio INC - Adr | — | EXIT | Sold out |
| 36 | DMRA | Damora Therapeutics INC | — | NEW | New buy |
| 37 | XNCR | Xencor INC | — | NEW | New buy |
| 38 | IVVD | Invivyd INC | — | EXIT | Sold out |
| 39 | IPSC | Century Therapeutics INC | — | NEW | New buy |
| 40 | MIRM | Mirum Pharmaceuticals INC | — | NEW | New buy |
| 41 | BIOA | Bioage Labs INC | — | NEW | New buy |
| 42 | AKTS | Aktis Oncology INC | — | NEW | New buy |
| 43 | ALXO | Alx Oncology Holdings INC | — | NEW | New buy |
| 44 | ACRS | Aclaris Therapeutics INC | — | NEW | New buy |
| 45 | TVTX | Travere Therapeutics INC | — | NEW | New buy |
| 46 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 47 | DRUG | Bright Minds Biosciences INC | — | NEW | New buy |
| 48 | STRO | Sutro Biopharma INC | — | NEW | New buy |
| 49 | AVR | Anteris Technologies Global | — | NEW | New buy |
| 50 | OKUR | Onkure Therapeutics Inc-a | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-14 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-17 | Amendment | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-15 | Amendment | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-14 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-15 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-14 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-15 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-16 | Amendment | View on EDGAR |
| 2016-12-31 | 2017-02-16 | Amendment | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-13 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-13 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-07-06 | Amendment | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-14 | 13F-HR | View on EDGAR |
| 2013-06-30 | 2013-08-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001687509
Total reported value
$9.4B
83 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001303159
Total reported value
$9.4B
468 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001535385
Total reported value
$9.4B
203 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0001176347
Total reported value
$620.1M
4 stks
2026-03-31
1 of the top 5 holdings overlap, including Rhythm Pharmaceuticals INC
CIK 0001177719
Total reported value
$23.8B
250 stks
2026-03-31
1 of the top 5 holdings overlap, including Ascendis Pharma A/S
CIK 0001224962
Total reported value
$5.1B
94 stks
2026-03-31
1 of the top 5 holdings overlap, including Ascendis Pharma A/S